Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Australia Outlines Sweeping Healthcare Reforms That Put Onus On Central Government

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Australian Prime Minister Kevin Rudd March 3 outlined sweeping changes to the nation's healthcare system, which would shift the fiscal burden to the federal government rather than the eight state governments and territories

You may also be interested in...



Australian Prime Minister And West Australian Premier At Loggerheads Over Healthcare Bill

PERTH, Australia - Prime Minister Kevin Rudd said Australia is moving ahead with his new healthcare plan with or without Western Australia

Australian Prime Minister And West Australian Premier At Loggerheads Over Healthcare Bill

PERTH, Australia - Prime Minister Kevin Rudd said Australia is moving ahead with his new healthcare plan with or without Western Australia

Australia Has Cheapest Drugs Compared To OECD Countries, UK Says

PERTH, Australia - Australia has the lowest prices for new medicines among developed countries, according to a UK Department of Health report on the Pharmaceutical Price Regulation Scheme

Table

View full table

Related Content

Scrip
Tags:
Latest Headlines

Pipeline Watch: Five Approvals And 23 Phase III Updates

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

See All
UsernamePublicRestriction

Register

SC074411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By